How long does it take for gilteritinib to take effect? Do I need to take it all the time?

Gilteritinib is an oral, FMS-like tyrosine kinase tyrosine kinase 3 (FLT3) small molecule inhibitor, used as an antineoplastic agent in the treatment of FLT3 mutated acute myeloid leukemia. Giritinibis associated with moderate elevations in serum aminotransferases during treatment and is suspected of causing rare cases of clinically apparent acute liver injury.

Giritinib needs to be taken until resistance or intolerable toxicity occurs. The time to reach the maximumgiritinibconcentration after administration(tmaximum)is approximately between 4 and 6 hours after administration in a fasted state. Healthy adults take a single dose of 40mg of GIRItinib (recommended dose0.3 times), GI >RetinibCmaximum compared to the fasted state, when combined with a high-fat meal(approximately 800 to 1, 000 Total calories, 500 to 600Fat calories, 250Carbohydrate calories, 150Protein calories)reduced 26% when coadministered, and AUC decreased less than 10%. Mediantmaximum delay2 hours when taking geritinib with a high-fat meal. The half-life of Gretinib is 113 hours, and the estimated apparent clearance rate is 14.85l/ hours.

Age(20-87years old), gender, race, mild(Child-Pugh Alevel)or moderate(Child-Pugh Grade B)Liver function impairment and mild(creatinine clearance rate(CLCr) 50-80 mL/min)or moderate(CLCr 30-50 mL/min) Renal impairment does not have a clinically meaningful effect on the pharmacokinetics of girdatinib. The effect of severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CLCr ≤ 29 mL/min) on the pharmacokinetics of giltinib is unknown. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.